These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31636509)

  • 1. (-)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells.
    Wang J; Sun P; Wang Q; Zhang P; Wang Y; Zi C; Wang X; Sheng J
    Cancer Cell Int; 2019; 19():266. PubMed ID: 31636509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells.
    Milligan SA; Burke P; Coleman DT; Bigelow RL; Steffan JJ; Carroll JL; Williams BJ; Cardelli JA
    Clin Cancer Res; 2009 Aug; 15(15):4885-94. PubMed ID: 19638461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGCG overcomes gefitinib resistance by inhibiting autophagy and augmenting cell death through targeting ERK phosphorylation in NSCLC.
    Meng J; Chang C; Chen Y; Bi F; Ji C; Liu W
    Onco Targets Ther; 2019; 12():6033-6043. PubMed ID: 31440060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases.
    Sah JF; Balasubramanian S; Eckert RL; Rorke EA
    J Biol Chem; 2004 Mar; 279(13):12755-62. PubMed ID: 14701854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Epigallocatechin-3-Gallate on EGFR Signaling and Migration in Non-Small Cell Lung Cancer.
    Minnelli C; Cianfruglia L; Laudadio E; Mobbili G; Galeazzi R; Armeni T
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.
    Zhang X; Zhang H; Tighiouart M; Lee JE; Shin HJ; Khuri FR; Yang CS; Chen Z'; Shin DM
    Int J Cancer; 2008 Sep; 123(5):1005-14. PubMed ID: 18546267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The green tea catechin epigallocatechin gallate induces cell cycle arrest and shows potential synergism with cisplatin in biliary tract cancer cells.
    Mayr C; Wagner A; Neureiter D; Pichler M; Jakab M; Illig R; Berr F; Kiesslich T
    BMC Complement Altern Med; 2015 Jun; 15():194. PubMed ID: 26100134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells.
    Shimizu M; Deguchi A; Lim JT; Moriwaki H; Kopelovich L; Weinstein IB
    Clin Cancer Res; 2005 Apr; 11(7):2735-46. PubMed ID: 15814656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An EGCG Derivative in Combination with Nimotuzumab for the Treatment of Wild-Type EGFR NSCLC.
    Huang Y; Cuan X; Zhu W; Yang X; Zhao Y; Sheng J; Zi C; Wang X
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
    Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
    J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigallocatechin-3-gallate inhibits the growth and increases the apoptosis of human thyroid carcinoma cells through suppression of EGFR/RAS/RAF/MEK/ERK signaling pathway.
    Wu D; Liu Z; Li J; Zhang Q; Zhong P; Teng T; Chen M; Xie Z; Ji A; Li Y
    Cancer Cell Int; 2019; 19():43. PubMed ID: 30858760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2.
    Chang CM; Chang PY; Tu MG; Lu CC; Kuo SC; Amagaya S; Lee CY; Jao HY; Chen MY; Yang JS
    Oncol Rep; 2012 Nov; 28(5):1799-807. PubMed ID: 22923287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines.
    Wang MC; Liang X; Liu ZY; Cui J; Liu Y; Jing L; Jiang LL; Ma JQ; Han LL; Guo QQ; Yang CC; Wang J; Wu T; Nan KJ; Yao Y
    Oncol Rep; 2015 Jan; 33(1):239-49. PubMed ID: 25370413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.
    Zhou H; Fu LX; Li L; Chen YY; Zhu HQ; Zhou JL; Lv MX; Gan RZ; Zhang XX; Liang G
    J Ethnopharmacol; 2020 Oct; 261():113118. PubMed ID: 32621953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
    Freeman DJ; Bush T; Ogbagabriel S; Belmontes B; Juan T; Plewa C; Van G; Johnson C; Radinsky R
    Mol Cancer Ther; 2009 Jun; 8(6):1536-46. PubMed ID: 19509246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.
    Kang HN; Kim SH; Yun MR; Kim HR; Lim SM; Kim MS; Hong KW; Kim SM; Kim H; Pyo KH; Park HJ; Han JY; Youn HA; Chang KH; Cho BC
    Lung Cancer; 2016 May; 95():57-64. PubMed ID: 27040853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines.
    Masuda M; Suzui M; Weinstein IB
    Clin Cancer Res; 2001 Dec; 7(12):4220-9. PubMed ID: 11751523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigallocatechin gallate sensitizes cisplatin-resistant oral cancer CAR cell apoptosis and autophagy through stimulating AKT/STAT3 pathway and suppressing multidrug resistance 1 signaling.
    Yuan CH; Horng CT; Lee CF; Chiang NN; Tsai FJ; Lu CC; Chiang JH; Hsu YM; Yang JS; Chen FA
    Environ Toxicol; 2017 Mar; 32(3):845-855. PubMed ID: 27200496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.